Imugene (ASX:IMU) advances VAXINIA trial

February 03, 2023 12:04 PM AEDT | By Manisha
Follow us on Google News:


  • Imugene Limited’s Phase 1 MAST study has cleared cohort 2 of both the intravenous (IV) and intratumoral (IT) arms of the monotherapy trial.
  • The company will now commence cohort 1 of the combination study (with Pembrolizumab) and cohort 3 for both arms of the monotherapy dose escalation.
  • As per IMU, early data from patients dosed at low levels with CF33 oncolytic virus reflects immune activation in the tumour microenvironment.

Clinical-stage immuno-oncology company Imugene Limited (ASX:IMU) shares rose more than 8.9% just after the market opened on Thursday following an ASX announcement by the company. IMU shares were spotted trading at AU$0.160 per share at 11:18 AM AEDT on 02 February 2023.

Imugene announced that its Phase 1 MAST (metastatic advanced solid tumours) clinical trial has cleared cohort 2 of both the intravenous (IV) and intratumoral (IT) arms of the monotherapy trial. This has led way for the trial to kick start cohort 1 of the combination study (with Pembrolizumab) and cohort 3 for both arms of the monotherapy dose escalation.

The Phase 1 MAST study is being undertaken with the objective to measure the safety of novel cancer-killing virus CF33- hNIS (VAXINIA).

Source: IMU update

Know more about the multicenter Phase 1 MAST trial

The clinical trial is titled “A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33- hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination with Pembrolizumab in Adult Patients with Metastatic or Advanced Solid Tumours (MAST).”

Imugene initiated the Phase 1 MAST study by administering a low dose of VAXINIA to enrolled subjects having metastatic or advanced solid tumours with minimum two prior lines of standard of care treatment. In preclinical laboratory and animal models, the City of Hope-developed oncolytic virus has been able to shrink ovarian, colon, lung, breast, and pancreatic cancer tumours.

To date, all those who have been treated in the monotherapy group have been given the lowest doses of VAXINIA. The patients have shown acceptable safety till now. This allows new study participants to get it in combination with the immunotherapy pembrolizumab.

Imugene started the study in May 2022. It is expected that the trial will be completed in about two years. Up to 100 patients will be recruited for the study across approximately 10 trial sites in the United States and Australia. 

Management commentary

Source: Company website


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK